"3-Iodobenzylguanidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
| Descriptor ID |
D019797
|
| MeSH Number(s) |
D02.078.370.510 D02.455.426.559.389.454.300 D02.455.526.581.496.300
|
| Concept/Terms |
3-Iodobenzylguanidine- 3-Iodobenzylguanidine
- 3 Iodobenzylguanidine
- MIBG
- meta-Iodobenzylguanidine
- meta Iodobenzylguanidine
- Iobenguane
- m-Iodobenzylguanidine
- m Iodobenzylguanidine
|
Below are MeSH descriptors whose meaning is more general than "3-Iodobenzylguanidine".
Below are MeSH descriptors whose meaning is more specific than "3-Iodobenzylguanidine".
This graph shows the total number of publications written about "3-Iodobenzylguanidine" by people in this website by year, and whether "3-Iodobenzylguanidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3-Iodobenzylguanidine" by people in Profiles.
-
High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
-
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 Apr 01; 48(4):320-323.
-
Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 May 01; 48(5):426-427.
-
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer. 2023 02 01; 30(2).
-
Time to resolution of iodine-123 metaiodobenzylguanidine (123 I-MIBG) avidity and local control outcomes for high-risk neuroblastoma following radiation therapy. J Med Imaging Radiat Oncol. 2023 Feb; 67(1):81-88.
-
Cystic adrenal masses: spectrum of multimodality imaging features and pathological correlation. Clin Radiol. 2022 07; 77(7):479-488.
-
Heterogeneous Head and Neck Paraganglioma With Distinct Features on 123 I-MIBG and 68 Ga-DOTATATE Images. Clin Nucl Med. 2022 Sep 01; 47(9):813-814.
-
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2021 10; 68(10):e29117.
-
[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma. Nucl Med Biol. 2020 Nov - Dec; 90-91:49-54.
-
High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. Curr Opin Endocrinol Diabetes Obes. 2020 06; 27(3):162-169.